针对NF-κB和NLRP3的纳米聚合物可降低神经炎症,并改善随着衰老和陶病变的认知功能
bioRxiv : the preprint server for biology
|February 19, 2024
概括
一种针对NF-κB和NLRP3信号通路的新纳米聚合物疗法减少了老化和陶病老鼠模型中的大脑炎症并改善了认知功能.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经炎症是与衰老和阿尔茨海默病相关的认知衰退的关键因素.
- NF-κB和NLRP3信号通路是这种神经炎症的主要驱动因素.
- 针对这些途径的现有治疗方法存在局限性,包括全身副作用和不良的临床转化.
研究的目的:
- 评估一种新型核酸治疗 (纳米聚合物) 尾酒,针对大脑中的NF-κB和NLRP3.
- 评估它在降低神经炎症和改善老年小鼠和病小鼠模型中的认知功能方面的有效性.
主要方法:
- 用NF-κB/NLRP3向纳米聚合物治疗老年野生型小鼠和rTg4510 tau病理小鼠4周.
- 分析神经炎症性细胞因子,质细胞激活和认知行为功能.
- 转录组分析以评估质相关炎症和神经元健康的变化.
主要成果:
- 在两种小鼠模型中,纳米聚合物治疗显著降低了大脑神经炎症性细胞因子.
- 在接受治疗后,老年小鼠和rTg4510小鼠的认知行为功能得到改善.
- 观察到质激活和病理的减少,与与炎症和神经元健康相关的基因表达的有利转变.
结论:
- 针对NF-κB和NLRP3的纳米聚合物有效地减少神经炎症并增强认知功能.
- 这些发现支持纳米聚合物作为与年龄相关的认知衰退和神经退行性疾病的治疗策略的潜力.
- 需要进一步的翻译研究来探索这种方法的临床应用.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484


